# Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

> **NCT02753504** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** CKD-519
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02753504
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753504, "Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02753504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*